Development and characterization of stable nanovesicular carrier for drug delivery
Source abstract
Abstract
Lipid vesicles are an important drug carrier which can serve for controlled delivery of drugs; however, these vesicles are quite unstable at ambient temperature and require stringent storage condition. Present work was done to develop a stable vesicular system for drug delivery. Vesicles of ceramide-2, cholesterol, cholesterol sulfate, and palmitic acid were prepared and compared with phosphatidylcholine vesicles for physicochemical parameters and accelerated stability. Diclofenac sodium was used as a model drug. Based on physicochemical parameter and in vitro release PCV-3 and CV-3 were selected for further studies in three different accelerated stability conditions. PCV-3 showed moderate changes at 4°C but was severely affected at 25°C and 40°C. CV-3 showed stable characteristics at 4°C and 25°C whereas at 40°C, CV-3 showed signs of slight modification owing to moisture absorption. Based on the study, CV-3 containing highest content of palmitic acid was found to be most stable.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (27)
Show source-provided references
1. 10.1080/0193269070171873510.1080/01932690701718735 ↗
2. 10.3109/10731199.2011.62228110.3109/10731199.2011.622281 ↗
3. Arifin DR · Artif Cells Blood Substit Immobil Biotechnol · 2005 · 33 · 11310.1081/BIO-200055874 ↗
4. 10.1111/j.2042-7158.1985.tb04990.x10.1111/j.2042-7158.1985.tb04990.x ↗
5. Baydoun L · Eur J Pharmaceut Biopharm · 2003 · 56 · 7310.1016/S0939-6411(03)00036-5 ↗
6. Blume G · J Liposome Research · 1992 · 2 · 35510.3109/08982109209010214 ↗
7. Dragicevic-Curic N · J Control Rel · 2008 · 127 · 5910.1016/j.jconrel.2007.12.013 ↗
8. 10.3109/0363904090341030010.3109/03639040903410300 ↗
9. 10.3109/21691401.2013.80008110.3109/21691401.2013.800081 ↗
10. Gaur PK · Pharmaceut Dev Tech · 2014 · 19 · 4810.3109/10837450.2012.751406 ↗
11. Goñi FM · . Biochim Biophys Acta · 2006 · 1758 · 190210.1016/j.bbamem.2006.09.011 ↗
12. 10.1016/S0378-5173(01)00896-110.1016/S0378-5173(01)00896-1 ↗
13. Kostarelos K · Adv Colloid Interface Sci · 2003 · 106 · 14710.1016/S0001-8686(03)00109-X ↗
14. Li X · Macromolecul Rapid Comm · 2007 · 28 · 66010.1002/marc.200600723 ↗
15. Lintner K · Int J Cosmetic Sci · 1997 · 19 · 1510.1111/j.1467-2494.1997.tb00162.x ↗
16. Liu D · J Nanopart Res · 2011 · 13 · 237510.1007/s11051-010-9998-y ↗
17. Moore DJ · Acta Dermatologica Venereol Supp · 2000 · 208 · 16
18. 10.1080/0265204080205541110.1080/02652040802055411 ↗
19. Sinico C · J Control Rel · 2005 · 103 · 12310.1016/j.jconrel.2004.11.020 ↗
20. Touitou E · J Control Rel · 2000 · 65 · 40310.1016/S0168-3659(99)00222-9 ↗
21. Walters KA · Transdermal and Dermatological Formulations · 2002 · 110.1201/9780824743239.ch1 ↗
22. Wartewig S · Skin Pharmacol Physiol · 2007 · 20 · 22010.1159/000104420 ↗
23. Weber TM · J Clin Aesthet Dermatol · 2012 · 5 · 29
24. Wertz PW · J Inves Dermatol · 1986 · 87 · 58210.1111/1523-1747.ep12455832 ↗
25. Yadav AV · Ind J Pharm Edu Res · 2011 · 45 · 402
26. 10.1016/0163-7258(81)90006-110.1016/0163-7258(81)90006-1 ↗
27. Zheng S · Biomater Artif Cells Immobilization Biotechnol · 1992 · 20 · 35510.3109/10731199209119655 ↗